Rapt Therapeutics (RAPT) | Stock Overview & Key Data
Rapt Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $58.02 on March 2, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Rapt Therapeutics
RAPT
|
1.68B Small-cap | 0.05% | 0.55% | 66.03% | 336.82% | 82.14% | 541.70% | -70.64% | -67.47% | -42.90% | -42.90% | -42.90% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Stoke Therapeutics
STOK
|
2.07B Mid-cap | 3.45% | -0.27% | -11.66% | -9.04% | -2.91% | 158.63% | 129.38% | -23.01% | 9.27% | 9.27% | 9.27% |
|
Tyra Biosciences
TYRA
|
2.18B Mid-cap | 6.73% | -22.92% | -22.86% | 29.07% | 6.57% | 158.77% | 58.76% | 35.56% | 35.56% | 35.56% | 35.56% |
|
Ultragenyx
RARE
|
2.37B Mid-cap | 17.55% | 1.52% | 16.32% | -29.95% | 7.54% | -35.05% | -49.57% | -74.35% | -55.72% | -42.37% | -42.37% |
Ownership & Short Interest
Calculate Your Rapt Therapeutics Investment Returns
Long-Term Investment Performance Analysis
Rapt Therapeutics stock price in Oct 2019 was $101.60, A $1,000.00 lump sum investment in Rapt Therapeutics made 6 years ago would be worth approximately $570.96 today, representing a negative return of -42.90%. This translates to an annualized return (CAGR) of -8.44%.
6 Years 4 Months Investment Scenario (Oct 2019 - Mar 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is RAPT's 52-week high and low?
- In the last 52 weeks, Rapt Therapeutics reached a high of $58.01 (on March 6, 2026) and a low of $5.66 (on May 15, 2025).
- What is the market cap and P/E ratio for RAPT?
- Curious about Rapt Therapeutics's size and valuation? Its market capitalization stands at 1.68B. When it comes to valuation, the P/E ratio (trailing twelve months) is -2.27, and the forward P/E (looking ahead) is -21.38.
- Does RAPT pay dividends? If so, what's the yield?
- As for dividends, Rapt Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Rapt Therapeutics's main competitors or similar companies to consider before investing?
When looking at Rapt Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Stoke Therapeutics
STOK2.07B Healthcare Biotechnology 158.63% 129.38% Tyra Biosciences
TYRA2.18B Healthcare Biotechnology 158.77% 58.76% Ultragenyx
RARE2.37B Healthcare Biotechnology -35.05% -49.57% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Rapt Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Rapt Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -85.37%, the Debt to Equity ratio from the most recent quarter is 1.71, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for RAPT?
- Looking at Rapt Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of RAPT stock is held by insiders and institutions?
- Wondering who owns Rapt Therapeutics stock? Company insiders (like executives and directors) hold about 0.28% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 110.57%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.